EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity

Eric L Bolf, Thomas C Beadnell, Madison M Rose iD, Angelo D'Alessandro iD, Travis Nemkov iD, Kirk C Hansen, Rebecca E Schweppe iD

Cells · 2023

DOI: 10.3390/cells12101374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Eric L Bolf und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism, and Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Mail Stop 8106, Aurora, CO 8…. Hauptthemen laut MEDLINE: src-Family Kinases, Thyroid Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health (NIH) National Cancer Institute (NCI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid cancer is the most common endocrine neoplasm, and despite its overall high survival rate, patients with metastatic disease or tumors that resist radioactive iodine experience a significantly worse prognosis. Helping these patients requires a better understanding of how therapeutics alter cellular function. Here, we describe the change in metabolite profiles after treating thyroid cancer cells with the kinase inhibitors dasatinib and trametinib. We reveal alterations to glycolysis, the TCA cycle, and amino acid levels. We also highlight how these drugs promote short-term accumulation of the tumor-suppressive metabolite 2-oxoglutarate, and demonstrate that it reduces the viability of thyroid cancer cells in vitro. These results show that kinase inhibition profoundly alters the metabolome of cancer cells and highlight the need to better understand how therapeutics reprogram metabolic processes, and ultimately, cancer cell behavior.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

src-Family KinasesThyroid NeoplasmsHumansDasatinibIodine RadioisotopesProtein Kinase InhibitorsCell Line, TumorPyridonesPyrimidinones

Stichwörter der Autor:innen

MAPKSrccombinationdasatinibmetabolismmetabolomicsthyroid cancertrametinib

Substanzen

Dasatinibsrc-Family KinasesIodine RadioisotopesProtein Kinase InhibitorstrametinibPyridonesPyrimidinones

Autor:innen und Institutionen

  • Division of Endocrinology, Metabolism, and Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Mail Stop 8106, Aurora, CO 80045, USA.
  • Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

ORCID-Profile: Madison M Rose, Angelo D'Alessandro, Travis Nemkov, Rebecca E Schweppe

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health (NIH) National Cancer Institute (NCI)
  • University of Colorado Cancer Center’s Lung, Head and Neck Cancer SPORE Pilot Award, Cancer League of Colorado
  • University of Colorado Cancer Center Support Grant
  • American Cancer Society

Zitieren

APA

Bolf, E. L., Beadnell, T. C., Rose, M. M., D'Alessandro, A., Nemkov, T., Hansen, K. C., & Schweppe, R. E. (2023). Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity. Cells. https://doi.org/10.3390/cells12101374

Vancouver

Bolf EL, Beadnell TC, Rose MM, D'Alessandro A, Nemkov T, Hansen KC, et al. Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity. Cells. 2023. doi:10.3390/cells12101374

BibTeX
@article{Bolf2023,
  author = {Bolf, Eric L and Beadnell, Thomas C and Rose, Madison M and D'Alessandro, Angelo and Nemkov, Travis and Hansen, Kirk C and Schweppe, Rebecca E},
  title = {Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12101374}
}
Kostenlos starten →